Derniers articles

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial

AbstractBackground: The impact of adapted physical activity (APA) on health-related quality of life (HRQoL) in...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : J Natl Compr Canc Netw.

New Biomarkers to Define A Biological Borderline Situation for Pancreatic Adenocarcinoma - Results of An Ancillary Study of the PANACHE01-PRODIGE48 Trial.

AbstractObjective: To investigate in patients treated for a resectable pancreatic ductal adenocarcinoma (PA), the...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Annals of Surgery

A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ study

AbstractBackground: The planification of radiation therapy (RT) for pancreatic cancer (PC) requires a dosimetric...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Radiation Oncology

Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort

AbstractKeywords: Biliary tract cancer; CisGem; Molecular profile; Real-life data.

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Digestive and Liver Disease

Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases

AbstractBackground: Small bowel adenocarcinoma is a rare disease. The genomic profiling tumours according to...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Br J Cancer.

Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort

AbstractBackground & aims: Accumulating data has shown the rising incidence and poor prognosis of early-onset...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Liver Int.

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study

AbstractBackground: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : JNCI Cancer Spectr.

État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi

AbstractOverview of biliary tract cancer management practices in France: results of the ACABi national survey...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Bull Cancer

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

AbstractBackground: We evaluated the value of pre-treatment positron-emission tomography-computed tomography...

Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : Cancers (Basel)

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

AbstractPurpose: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Journal of Clinical Oncology

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"

AbstractIntroduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clinical colorectal cancer

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study

AbstractPurpose: This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : European journal of cancer

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

AbstractBackground: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Frontiers in oncology

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Cancer Res .

Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

AbstractCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Mol Oncol .

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

AbstractBackground: The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients,...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Ann Oncol

An international tool to measure perceived stressors in intensive care units: the PS-ICU scale

AbstractBackground: The intensive care unit is increasingly recognized as a stressful environment for healthcare...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Ann Intensive Care .

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Int J Cancer

Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Res Hepatol Gastroenterol

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial

AbstractImportance: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : JAMA Netw Open .

Exposure-response analysis of Raltitrexed assessing liver toxicity

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Br J Clin Pharmacol

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

AbstractMismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI) colorectal cancers (CRC) represent...

Posté par : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Nom de la revue : Int J Cancer

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...

Posté par : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Nom de la revue : J Clin Oncol

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : J Natl Cancer Inst

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

AbstractPurpose: The aim of this study was to investigate the association between expression of insulin-like growth...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : Cell Oncol (Dordr)

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractBackground: The variability of definitions for time-to-event (TTE) end-points impacts the conclusions of...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Nom de la revue : Eur J Cancer

01 February, 2020

Absorbable Polyglactin vs. Non-Cross-linked Porcine Biological Mesh for the Surgical Treatment of Infected Incisional Hernia

AbstractBackground: The use of absorbable meshes during contaminated or infected incisional hernia (IH) repair is...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : J Gastrointest Surg

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Oncologist

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

AbstractBackground: To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : Cancer Imaging

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

AbstractBackground: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : Lancet

Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF)

AbstractBackground: Failed kidney transplant is becoming a frequent cause of dialysis initiation. Although studies...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Nephrol Dial Transplant

Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer

AbstractObjective: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic...

Posté par : Mme. Julie HENRIQUES, Pr. Franck BONNETAIN
Nom de la revue : BJU Int

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

ABSTRACTBackground: Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : The Breast

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

PurposeThe aim of this study was to determine the prevalence of adherence to adjuvant hormonal therapy (AHT) and to...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Breast Cancer Research and Treatment

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

AbstractBackground: Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Breast Cancer Research

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort

Abstract Aim: Adjuvant clinical trials in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : European Journal of Cancer

 Archives

 Contributor